Hamill John P. 4

What Happened

• John P. Hamill, Sr. VP, Chief Financial Officer and Principal Financial & Accounting Officer of Aprea Therapeutics (APRE), participated in a private placement that closed March 31, 2026. He acquired 30,978 pre-funded warrants and 30,978 accompanying common warrants. The reported cost for the pre-funded warrants was $0.81 each, totaling $24,999 (reported as a derivative acquisition). The filing lists the transaction as a purchase (code P), which is a net acquisition of potential future shares rather than an outright purchase of common stock.

Key Details

• Transaction date: March 31, 2026; Form 4 filed April 1, 2026 (timely).
• Reported amount: 30,978 pre-funded warrants and 30,978 common warrants.
• Reported price/value: Pre-funded warrants at $0.81 each; total reported value $24,999.
• Shares owned after transaction: Not specified in the provided summary (not disclosed here).
• Footnotes of note:
  • The pre-funded warrants were issued in a private placement under a securities purchase agreement and are immediately exercisable.
  • Exercise is subject to a Beneficial Ownership Limitation: exercise cannot cause the holder (with affiliates) to exceed 4.99% of outstanding common stock or 9.99% of combined voting power.
  • Common warrants are immediately exercisable subject to the same ownership limit and expire on December 31, 2029 (or 30 days after any pre-funded warrant exercise, pro rata).
• Transaction code: P = Purchase (derivative securities).

Context

• A pre-funded warrant is effectively a nearly-paid-for right to receive common stock after paying a nominal exercise price; it’s often used so an investor can buy equity without immediately increasing a company’s public float above certain ownership thresholds.
• This is an acquisition of derivative securities (warrants), not an outright purchase of common shares. Such purchases show the insider has the option to acquire shares later but do not immediately change public share count unless exercised.
• Purchases by officers are often considered more informative than sales, but they do not by themselves indicate future company performance.